Advertisement

Topics

Search Results for "Crizotinib Src Kinase"

01:11 EDT 30th April 2017 | BioPortfolio

Matching Channels

Polo like kinase Plk 1

Polo-like kinase (Plk) is an important cell cycle regulatory kinase that has been implicated in a multitude of cell cycle events. Plks form a family of four different proteins that regulates many as...

MAP kinase kinase MEK Inhibitors

The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death.  The MAPK pathway has emerged as the crucial route between membrane-bound Ras...

Bcr Abl and Src Kinase Inhibitors

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t...

Checkpoint kinase 1 CHK 1

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumo...

Kinases Raf Inhibitors

The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or...

Matching News

Phase III Study Shows Roche's Alecensa Improves PFS Over Crizotinib in ALK-positive NSCLC

Roche said a second Phase III study has shown that non-small-cell lung cancer (NSCLC) patients treated with its oral anaplastic lymphoma kinase ( ALK) inhibitor Alecensa ® (alectinib) stayed aliv...

[Comment] First-line treatment options for -rearranged lung cancer

One of the most important advances in lung cancer this past decade was the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in 3–7% of non-small-cell lung cancers (NSCLCs) and ...

Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer

Roche today announced that the global, randomised phase III ALEX study met its primary endpoint and showed that Alecensa® (alectinib) as an initial (first-line) treatment significantly reduced the ri...

Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global, randomised phase III ALEX study met its primary endpoint and showed that Alecensa® (alectinib) as an initial (first-line) treatment...

PhIII Study Shows Roche's Alecensa Improves PFS Over Crizotinib in ALK-positive NSCLC

Roche said a second Phase III study has shown that non-small cell lung cancer (NSCLC) patients treated with its oral ALK inhibitor Alecensa® (alectinib), stayed alive without their disease worsen...

Ariad seeks European approval for NSCLC drug brigatinib

Ariad Pharmaceuticals is seeking approval in Europe for brigatinib to treat adult patients anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) who have been earlier treated with crizo...

Alectinib Notches Trial Win Against Crizotinib

Roche's Alecensa (alectinib) kept people with a specific lung cancer alive longer without their disease progressing than Pfizer's Xalkori (crizotinib), the Swiss drugmaker said on Monday, as it seeks ...

Assay Identifies Crizotinib-Eligible Lung Cancer Patients

An IHC assay for ALK status in non-small cell lung cancer tumor tissue predicts crizotinib treatment outcomes and offers a rapid and potentially less expensive alternative to older FISH ALK status ass...

Matching PubMed Articles

AREG triggered EGFR activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by EGFR inhibitors.

Crizotinib, a first-generation anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor, is known to be effective against echinoderm microtubule-associated protein-like 4 (EML4)-ALK-positive non-sma...

Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report.

Lung cancer with ovarian metastasis or adnexal metastasis harboring anaplastic lymphoma kinase (ALK) gene translocation is rare. Crizotinib, a novel ALK tyrosine kinase inhibitor, has already shown an...

Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer.

Crizotinib (250 mg twice daily) is the first anaplastic lymphoma kinase (ALK) inhibitor approved for treatment of ALK-positive non-small-cell lung cancer (NSCLC). The objectives of the current study ...

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.

Malignant pleural mesothelioma (MPM) is an aggressive cancer that is commonly associated with prior asbestos exposure. Receptor tyrosine kinases (RTKs) such as MET and its downstream target PI3K are o...

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.

The first-in class ALK/c-MET/ROS1 inhibitor crizotinib (Xalkori) has shown remarkable clinical efficacy in treatment of ALK-positive NSCLC. In neuroblastoma, activating mutations in the ALK kinase dom...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement